<div id="readability-page-1"><ul><li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li></ul><p>Executives from <strong>AbbVie <span>NYSE: ABBV<span></span></span></strong> outlined upcoming clinical milestones and development priorities across hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), and several earlier-stage immunology programs during a recent discussion focused on differentiation, combination strategies, and next-generation platforms.</p><h2>HS: IL-1 bispecific lutikizumab and RINVOQ readouts expected by year-end</h2> <p>Company leaders emphasized that HS remains a significant unmet-need area and highlighted AbbVie’s long history in the indication, noting HUMIRA was the first medicine approved for HS. They said AbbVie’s current HS strategy centers on targeted development of lutikizumab (an IL-1 alpha/IL-1 beta bispecific) and RINVOQ, with an emphasis on clinical differentiation in both biologic-naive and biologic-experienced populations. </p><ul><li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li></ul><p>Discussing mechanism, AbbVie said neutrophils play an important role in HS and are not directly targeted by current therapies. Executives described IL-1 alpha as an “alarmin” released from keratinocytes and IL-1 beta as recruiting neutrophils to lesional skin, arguing the two cytokines have “non-redundant and synergistic roles” that support blocking both. </p><p>On clinical data, AbbVie characterized lutikizumab’s phase 2 results as “really strong,” including in TNF-experienced patients as well as a separate treatment-naive cohort. Management also noted that the original phase 2 TNF-failure group included a high proportion of advanced disease, including many patients described as early stage three with draining fistulas and tunnels. </p><ul><li>AbbVie Call Options Spike 2,599%: Tracking the Big Bet</li></ul><p>Looking ahead, the company said it has opened a phase 2 program that includes both biologic-experienced and biologic-naive patients for lutikizumab, while RINVOQ development in HS is focused on a 100% TNF-experienced population. AbbVie said both programs are expected to have double-blind week 16 data by the end of this year.  </p><h2>Competitive framing in HS: safety, immunogenicity, and IL-1 alpha/beta rationale</h2> <p>In discussing the HS development landscape, AbbVie addressed several external approaches and highlighted considerations that could influence differentiation. Management referenced recent developments in OX40 programs in atopic dermatitis, including discussion of Kaposi’s sarcoma events, and said that dermatology prescribing can be sensitive to signals suggesting stronger immunosuppression over long-term use. </p><p>They also discussed challenges that can arise with anti-TNF bispecifics, including immunogenicity. AbbVie cited its own historical experience with a TNF-17 program that had a high level of immunogenicity, suggesting that “making bispecifics with anti-TNFs” can be more difficult. </p><p>On IL-1 strategies, executives reiterated their preference for targeting IL-1 alpha as well as IL-1 beta, noting IL-1 alpha’s role in epidermal damage signaling and potential implications such as increased angiogenesis and inflammation. They argued that blocking both cytokines may also help address compensatory mechanisms.  </p><h2>IBD: subcutaneous SKYRIZI data and a broad combination roadmap</h2> <p>In IBD, AbbVie previewed multiple readouts and positioned combination therapy as a path toward higher efficacy, deeper remission, and more durable outcomes. Management said subcutaneous data for SKYRIZI are expected this year and could be important competitively in a market where some rivals offer subcutaneous options. AbbVie added that it currently sees strong front-line share for SKYRIZI and believes a subcutaneous option could further support usage. </p><p>On combinations, AbbVie described a mix of “precedented” and novel mechanisms under evaluation alongside SKYRIZI. They highlighted several approaches they see as orthogonal to IL-23: </p><ul>   <li><strong>Alpha-4 beta-7</strong>: described as a more potent version compared with vedolizumab; a readout is expected this year.</li>   <li><strong>TL1A</strong>: AbbVie said TL1A has shown convincing phase 2 efficacy across the class, particularly stronger in ulcerative colitis than Crohn’s disease; SKYRIZI/TL1A combination studies are expected to start later this year.</li>   <li><strong>Lutikizumab</strong>: AbbVie said it looked numerically better than HUMIRA in ulcerative colitis but not as high as desired, and it will be tested in Crohn’s disease, including in combination with alpha-4 beta-7.</li>   <li><strong>TREM1</strong>: positioned as a unique, upstream inflammation-amplification mechanism with proof-of-concept expected later this year or early next year.</li> </ul>  <h2>TL1A: combination strategy, biomarkers, and possible anti-fibrotic relevance</h2> <p>Management said TL1A is a mechanism AbbVie views as validated by multiple phase 2 datasets, but they did not see differentiated efficacy versus SKYRIZI or RINVOQ based on what had been available to date. As a result, AbbVie said its strategy is to pursue combination approaches to “break that efficacy ceiling,” while maintaining safety and offering convenience through potential co-formulations. </p><p>AbbVie also discussed biomarkers as a potential future path to more individualized treatment in IBD and immunology, though executives noted immunology has been more challenging than oncology in identifying robust predictive biomarkers. The company said it continues to collect tissue samples in studies and work with internal precision medicine efforts, and noted TL1A had shown “glimpses” of biomarker potential. </p><p>On broader development potential for its TL1A asset, the company said TL1A has preclinical support for anti-fibrotic activity and noted that unchecked inflammation can lead to irreversible fibrosis. AbbVie said diseases such as rheumatoid arthritis, psoriatic arthritis, HS, and systemic sclerosis are on its radar for potential future consideration. The company also referenced an internal LPAR program that has entered the clinic and is aimed at immune and fibrosis biology, including programs in idiopathic pulmonary fibrosis and sclerosis.  </p><h2>Earlier-stage platforms: oral IL-23 ambitions and B-cell-focused programs</h2> <p>AbbVie also outlined its rationale for pursuing an oral IL-23 program through its Nimble deal, emphasizing goals of higher potency and longer half-life. Executives said adherence can be difficult with daily oral therapies and argued that maximizing IL-23 blockade is important to deliver outcomes comparable to SKYRIZI across psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. They added that oral IL-23 data seen to date have not matched SKYRIZI-like efficacy, which they attributed in part to half-life and potency limitations. </p><p>In B-cell-directed approaches, AbbVie discussed an antibody-drug conjugate program referred to as 319, described as a CD19-targeting ADC with a steroid payload. Executives said the program combines three mechanisms: delivering steroid to B-cells, inhibiting CD19 activation, and antibody-dependent killing. They also referenced an additional related asset, ABBV-519, described as the same antibody without the payload, which they said could be used as a steroid-free option for maintenance or boosting if needed. Separately, the company noted a Capstan partnership for an “in situ lipid nanoparticle CAR-T” approach, describing it as not requiring lymphodepletion, lacking DNA integration, tunable, re-dosable, and transiently expressed.</p><h2>About AbbVie <span>NYSE: ABBV<span></span></span></h2><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Read More</h2><ul><li>Five stocks we like better than AbbVie</li><li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li><li>They just tried to kill gold</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Trump &amp; Musk’s Secret Bet on Silver — Exposed</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Executives from AbbVie (NYSE:ABBV) discussed upcoming clinical milestones in hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD) during a recent conference. They highlighted the development of lutikizumab and RINVOQ for HS, with promising phase 2 results expected by year-end. In IBD, AbbVie previewed subcutaneous SKYRIZI data and a combination therapy roadmap aimed at enhancing efficacy and durability. The company emphasized the importance of targeting IL-1 alpha and beta in HS and outlined various combination strategies for IBD, including potential co-formulations and biomarker research for individualized treatment.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Abbvie

ALPS Medical Breakthrough

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus